-
Posted by
Two Blokes 10 hours ago -
Filed in
Stock
-
2 views
Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON , June 20, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and its full year Adjusted EBITDA guidance of $135M-165M.
